气道微生物群调节阿奇霉素对学龄前儿童反复哮喘样症状发作的疗效:一项随机临床试验
本研究基于COPSAC2010队列,纳入68名12-36月龄反复哮喘样症状患儿,在急性发作期随机接受阿奇霉素或安慰剂,分析咽后壁吸出物16S rRNA测序。结果发现气道微生物群丰富度与发作持续时间相关,并修饰阿奇霉素疗效;丰富度越高,阿奇霉素缩短发作的效果越强。
要点
- 气道微生物丰富度每增加10个OTU,发作持续时间延长7.5%(95%CI 1-14%,P=0.025)。
- 治疗前微生物丰富度每增加10个OTU,阿奇霉素疗效增加10%。
- 五个具体OTU对阿奇霉素疗效有修饰作用(q<0.05)。
核心结论
- 急性哮喘样症状发作时的气道微生物群与发作持续时间相关,并修饰学龄前儿童阿奇霉素治疗效果。
研究设计与样本
- 基于COPSAC2010队列的随机临床试验,68名12-36月龄反复哮喘样症状患儿在急性发作期随机接受阿奇霉素或安慰剂。
- randomization前采集咽后壁吸出物,行16S rRNA基因扩增子测序,共139份气道样本。
主要发现
- 微生物丰富度每增加10个OTU,发作持续时间延长7.5%(95%CI 1-14%,P=0.025)。
- 15个个体OTU(包括若干奈瑟菌和韦荣球菌)及基于加权UniFrac距离定义的微生物 pneumotype 与发作持续时间相关,以奈瑟菌主导型持续时间最长。
- 治疗前微生物丰富度每增加10个OTU,阿奇霉素疗效增加10%;与阿奇霉素疗效增加正相关的OTU多于负相关(82 vs. 58;P=0.0032)。
- 五个个体OTU对阿奇霉素疗效有修饰作用(三个增加疗效、两个降低疗效;q<0.05)。
临床怎么用
- 对于反复哮喘样症状的学龄前儿童,急性发作时气道微生物群特征可能有助于识别阿奇霉素治疗获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Childhood asthma is often preceded by recurrent episodes of asthma-like symptoms, which can be triggered by both viral and bacterial agents. Recent randomized controlled trials have shown that azithromycin treatment reduces episode duration and severity through yet undefined mechanisms. Objectives: To study the influence of the airway microbiota on the effect of azithromycin treatment during acute episodes of asthma-like symptoms. Methods: Children from the COPSAC2010 (Copenhagen Prospective Studies on Asthma in Childhood 2010) cohort with recurrent asthma-like symptoms aged 12-36 months were randomized during acute episodes to azithromycin or placebo as previously reported. Before randomization, hypopharyngeal aspirates were collected and examined by 16S ribosomal RNA gene amplicon sequencing. Measurements and Main Results: In 139 airway samples from 68 children, episode duration after randomization was associated with microbiota richness (7.5% increased duration per 10 additional operational taxonomic units [OTUs]; 95% confidence interval, 1-14%; P = 0.025), with 15 individual OTUs (including several Neisseria and Veillonella), and with microbial pneumotypes defined from weighted UniFrac distances (longest durations in a Neisseria-dominated pneumotype). Microbiota richness before treatment increased the effect of azithromycin by 10% per 10 additional OTUs, and more OTUs were positively versus negatively associated with an increased azithromycin effect (82 vs. 58; P = 0.0032). Furthermore, effect modification of azithromycin was found for five individual OTUs (three OTUs increased and two OTUs decreased the effect; q < 0.05). Conclusions: The airway microbiota in acute episodes of asthma-like symptoms is associated with episode duration and modifies the effect of azithromycin treatment of the episodes in preschool children with recurrent asthma-like symptoms. Clinical trial registered with www.clinicaltrials.gov (NCT01233297).
引用
- Thorsen J, Stokholm J, Rasmussen MA, et al. The Airway Microbiota Modulates Effect of Azithromycin Treatment for Episodes of Recurrent Asthma-like Symptoms in Preschool Children: A Randomized Clinical Trial. Am J Respir Crit Care Med. 2021. PMID: 33730519. doi:10.1164/rccm.202008-3226OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。